
SNN Stock Forecast & Price Target
SNN Analyst Ratings
Bulls say
Smith & Nephew's financial outlook remains positive, bolstered by a strong underlying revenue growth of 5.3%, excluding challenges in China, and expectations for continued strength in U.S. sports medicine and advanced wound therapy segments. Key growth drivers include a significant 23.9% increase in other reconstruction revenues, spurred by record CORI placements, along with a projected trading profit margin between 19.0% and 20.0% for 2025, suggesting operational efficiencies and cost improvements. Furthermore, the company anticipates a stronger second half of the year, supported by sustained demand in its orthopedic products and an overall group revenue growth of 4.7%.
Bears say
Smith & Nephew faces a challenging outlook due to weaker revenue guidance for FY25, influenced by factors such as a reduced number of selling days, distributor inventory adjustments in China, and anticipated negative impacts from Value-Based Pricing (VBP) initiatives, particularly in the Advanced Wound Therapy segment. The company's return on invested capital (ROIC) within the orthopedic segment is a concern, as it remains significantly lower than its other business units, which could hinder profitability. Additionally, ongoing risks related to political stability and regulatory changes in emerging markets, along with potential decreases in reimbursement rates in the evolving U.S. healthcare landscape, further contribute to the negative outlook on the company's financial performance.
This aggregate rating is based on analysts' research of Smith & Nephew and is not a guaranteed prediction by Public.com or investment advice.
SNN Analyst Forecast & Price Prediction
Start investing in SNN
Order type
Buy in
Order amount
Est. shares
0 shares